Comparison of the effects of feeding quercetin or flavone on hepatic and intestinal drug-metabolizing enzymes of the rat

doi:10.1016/0278-6915(88)90105-6

Food and Chemical Toxicology

Volume 26, Issue 2, 1988, Pages 99-103

https://doi.org/10.1016/0278-6915(88)90105-6 Get rights and content

Abstract

The influence of dietary flavone and quercetin on the components of the drug metabolizing enzyme system was examined in the liver and small intestine of the rat. Quercetin given at a concentration of 1% in the diet for 14 days produced no significant changes on phase I or phase II enzyme activities. In contrast, 0.25% flavone caused significant increases in relative liver weight, microsomal and cytoplasmic proteins, and cytochrome P-450 content. The activities of hepatic ethoxyresorufin, pentoxyresorufin and ethoxycoumarin deethylases were significantly increased (by 20, 30 and 2.5-fold, respectively) over control levels. Hepatic UDP-glucuronyl transferase and glutathione transferase activities were increased 3–4-fold. In contrast, flavone induced no changes in these two intestinal enzyme activities. It is concluded that flavone produces an induction that shows both phenobarbital- and methylcholanthrene-type characteristics and that its effect on conjugating enzymes is tissue specific.

References (35)

K.W. Bock et al.
Effects of phenobarbital and 3-methylcholanthrene on substrate specificity of rat liver microsomal UDP-glucuronyltransferase
Biochim. biophys. Acta
(1973)
A.N. Booth et al.
The metabolic fate of rutin and quercetin in the animal body
J. biol. Chem.
(1956)
B. Burchell et al.
4-Nitrophenol UDP-glucuronyl transferase (rat liver)
M.D. Burke et al.
Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochrome P-450
Biochem. Pharmac.
(1985)
W.H. Habig et al.
Glutathione S-transferases
B. Havsteen
Flavonoids, a class of natural products of high pharmacological potency
Biochem. Pharmac.
(1983)
M.T. Huang et al.
Specificity in the activation and inhibition by flavonoids of benzo(a)-pyrene hydroxylation by cytochrome P-450 isozymes from rabbit liver microsomes
J. biol. Chem.
(1981)
O.H. Lowry et al.
Protein measurement with the Folin phenol reagent
J. biol. Chem.
(1951)
R.A. Lubet et al.
Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat
Archs Biochem. Biophys.
(1985)
T. Omura et al.
The carbon monoxide-binding pigment of liver microsomes

A.H. Phillips et al.

Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization and kinetics studies

J. biol. Chem.

(1962)

R.L. Sousa et al.

Inhibition of cytochrome P-450 activity in rat liver microsomes by the naturally occurring flavonoid, quercetin

Archs Biochem. Biophys.

(1985)

A. Vernet et al.

Comparison of the effects of various flavonoids on ethoxycoumarin deethylase activity of rat intestinal and hepatic microsomes

Fd Chem. Toxic.

(1986)

M.K. Buening et al.

Activation and inhibition of benzo(a)pyrene and aflatoxin B₁ metabolism in human liver microsomes by naturally occurring flavonoids

Cancer Res.

(1981)

M.D. Burke et al.

Ethoxyresorufin: direct fluorimetric assay of a microsomal O-dealkylation which is preferentially inductible by 3-methylcholanthrene

Drug Metab. Dispos.

(1974)

A.H. Conney

Pharmacological implications of microsomal enzyme induction

Pharmac. Rev., Lond.

(1967)

K.R. Cutruneo et al.

Induction of benzypyrene hydroxylase by flavone and its derivatives in fetal rat liver explants

Biochem. Pharmac.

(1972)

Cited by (42)

Structure-activity relationships of flavonoids as natural inhibitors against E. coli β-glucuronidase
2017, Food and Chemical Toxicology
Citation Excerpt :
Such features are very helpful for alleviating the inflammatory progression in patients with CPT-11 associated severe delayed-onset diarrhea. It has been reported that many flavonoids could modulate the catalytic activities of a variety of enzymes, thus plays an important role in endogenous and xenobiotic metabolism (Brouard et al., 1988; Xin et al., 2016; Tang et al., 2012). A previous study has reported that several natural flavonoids (such as baicalin and wogonoside) display strong inhibitory effects on E. coli β-glucuronidase (EcGUS), but the inhibitory effects of other natural flavonoids against EcGUS and the potential structure-inhibition relationships have not been well characterized (Narita et al., 1993).
Bacterial β-glucuronidases play key roles in the deconjugation of a variety of endogenous and drug glucuronides, thus have been recognized as important targets to modulate the enterohepatic circulation of various glucuronides. In this study, more than 30 natural flavonoids were collected and their inhibitory effects against E. coli β-glucuronidase (EcGUS) were assayed. The results demonstrated that some flavonoids including scutellarein, luteolin, baicalein, quercetin and scutellarin displayed strong to moderate inhibitory effects against EcGUS, with the IC₅₀ values ranging from 5.76 μM to 29.64 μM, while isoflavones and dihydroflavones displayed weak inhibitory effects against EcGUS. Further investigation on inhibition kinetics revealed that scutellarein and luteolin functioned as potent competitive inhibitors against EcGUS-mediated PNPG hydrolysis, with the K_i values less than 3.0 μM. Molecular docking simulations demonstrated that scutellarein and luteolin could be well-docked into the catalytic site of EcGUS, while the binding areas of these two natural inhibitors on EcGUS were highly overlapped with that of PNPG on EcGUS. Additionally, the structure-inhibition relationships of natural flavonoids against EcGUS are also summarized, which will be very helpful for the medicinal chemists to design and develop more potent flavonoid-type inhibitors against EcGUS.
Pharmacokinetic study of eplerenone in rats after long-term coadministration with buckwheat tea
2016, Kaohsiung Journal of Medical Sciences
Citation Excerpt :
An earlier study showed that there was no significant difference in Phase I or Phase II enzyme activities when quercetin was given for 14 days at a concentration of 1%. In contrast, the liver weight, protein content of microsomal and cytoplasmic, and activity of cytochrome P450 were substantially increased when 0.25% flavone was given [18]. It has been known that 6β-hydroxy eplerenone and 21-hydroxy eplerenone are the major metabolites in vitro in both humans and dogs, and that the metabolism of eplerenone was primarily mediated by CYP3A4 in humans and CYP3A12 in dogs [11].
The aim of this study was to investigate the effect of long-term intake of Tartary buckwheat tea on the pharmacokinetics (PK) of eplerenone in rats. A validated high-performance liquid chromatography-mass spectrometry (HPLC-MS) method was established to determine the eplerenone in plasma, and the portal vein absorption model was applied to conduct the pharmacokinetic study. Two groups of animals—buckwheat tea group and control group—were involved in this study. Plasma samples were obtained at different time points after administration, and were separated on Shimadzu HPLC-MS 2020 instruments. The method showed good linearity (r = 0.9988) over a wide dynamic range (0.20–50 μg/mL). Within- and between-batch precisions ranged from 2.13% to 7.90%. The extraction recovery rates ranged from 91.96% to 94.96%. The data showed that in the Tartarian buckwheat group the area under the curve and maximum concentration of eplerenone were reduced compared with those of the blank group (p < 0.01), but the time to reach peak concentrations of eplerenone (p < 0.01) was prolonged. The results suggested that long-term consumption of Tartary buckwheat tea might induce the activities of the hepatic drug metabolizing enzyme, which can accelerate the metabolism of eplerenone. According to the results, the dosage of eplerenone should be adjusted in hypertension treatment trials when administered with Tartary buckwheat or Tartary buckwheat-containing dietary supplements to avoid potential drug interactions.
Polyphenol-Mediated In Vivo Cellular Responses during Carcinogenesis
2013, Polyphenols in Human Health and Disease
Polyphenols are a large family of natural compounds widely distributed in plants and are the most studied chemopreventive agents. The biological activities and mechanism(s) of chemopreventive effects of polyphenols have been extensively studied. Therefore, this review focuses mainly on the evidence relating to chemopreventive efficacy of polyphenols and describing their mechanism(s) of anti-initiating, anti-promoting and anti-progressor action(s) in different in vivo experimental systems. Studies employing in vivo experimental rodent models have demonstrated several polyphenols to modulate incidence, multiplicity, latency period of carcinogen-induced tumors at various organ sites and tumor angiogenesis, metastasis and behavior of transplanted tumors/xenografts. The observed in vivo anti-initiating, anti-promoting and anti-progressor activity of polyphenols in chemical and genetic models involve modulation of signaling kinases ultimately leading to effects on genes and cell signaling pathways at multiple levels. Overall, the mechanism(s) implicated in the polyphenol(s)-mediated inhibition are diverse and involve effects on multiple molecular pathways and genes.
Estrogenic effect of the MEK1 inhibitor PD98059 on endogenous estrogen receptor alpha and beta
2011, Journal of Steroid Biochemistry and Molecular Biology
Citation Excerpt :
On the other hand, flavonoids are substrates to cytochrome P450 monooxygenases and phase II conjugation enzymes [8]. Particularly, flavone was shown to increase expression and activity of rat CYP1A2 [18], and to increase activity of UDP-glucuronoslytransferase [19]. Therefore, wether the estrogenic effect observed in PD98059 preparations is related to an ER binding contaminant, to a metabolic product or to the flavone nature of PD98059 which make it a potential ER ligand at μM concentrations (well within the EC50 for ER binding of other flavonoids) deserve further studies.
Estrogens are key regulators in mammary development and breast cancer and their effects are mediated by estrogen receptors alpha (ERα) and beta (ERβ). These two receptors are ligand activated transcription factors that bind to regulatory regions in the DNA known as estrogen responsive elements (EREs). ERα and ERβ activation is subject to modulation by phosphorylation and p42/p44 MAP kinases are the best characterized ER modifying kinases. Using a reporter gene (3X-ERE-TATA-luciferase) to measure activation of endogenous ERs, we found that MEK1 inhibitor PD98059, used in concentrations insufficient to inhibit MEK1 activation of p42/p44 MAP kinases, exerted estrogenic effects on the reporter gene and on the ERE-regulated RIP 140 protein. Such estrogenic effects were observed in mammary epithelial HC11 cells and occur on unliganded ERα and ligand activated ERβ. Additionally, concentrations of PD98059 able to inhibit p42/p44 phosphorylation were not estrogenic. Further, inhibition of p42 MAP kinase expression with siRNAs also resulted in loss of PD98059 estrogenic effect. In summary, PD98059 in concentrations below the inhibitory for MEK1, exerts estrogenic effects in HC11 mammary epithelial cells.
Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism
2006, Toxicology in Vitro
Flavonoids are present in fruits, vegetables and beverages derived from plants (tea, red wine), and in many dietary supplements or herbal remedies including Ginkgo Biloba, Soy Isoflavones, and Milk Thistle. Flavonoids have been described as health-promoting, disease-preventing dietary supplements, and have activity as cancer preventive agents. Additionally, they are extremely safe and associated with low toxicity, making them excellent candidates for chemopreventive agents. The cancer protective effects of flavonoids have been attributed to a wide variety of mechanisms, including modulating enzyme activities resulting in the decreased carcinogenicity of xenobiotics. This review focuses on the flavonoid effects on cytochrome P450 (CYP) enzymes involved in the activation of procarcinogens and phase II enzymes, largely responsible for the detoxification of carcinogens.
A number of naturally occurring flavonoids have been shown to modulate the CYP450 system, including the induction of specific CYP isozymes, and the activation or inhibition of these enzymes. Some flavonoids alter CYPs through binding to the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor, acting as either AhR agonists or antagonists. Inhibition of CYP enzymes, including CYP 1A1, 1A2, 2E1 and 3A4 by competitive or mechanism-based mechanisms also occurs. Flavones (chrysin, baicalein, and galangin), flavanones (naringenin) and isoflavones (genistein, biochanin A) inhibit the activity of aromatase (CYP19), thus decreasing estrogen biosynthesis and producing antiestrogenic effects, important in breast and prostate cancers. Activation of phase II detoxifying enzymes, such as UDP-glucuronyl transferase, glutathione S-transferase, and quinone reductase by flavonoids results in the detoxification of carcinogens and represents one mechanism of their anticarcinogenic effects. A number of flavonoids including fisetin, galangin, quercetin, kaempferol, and genistein represent potent non-competitive inhibitors of sulfotransferase 1A1 (or P-PST); this may represent an important mechanism for the chemoprevention of sulfation-induced carcinogenesis.
Importantly, the effects of flavonoids on enzymes are generally dependent on the concentrations of flavonoids present, and the different flavonoids ingested. Due to the low oral bioavailability of many flavonoids, the concentrations achieved in vivo following dietary administration tend to be low, and may not reflect the concentrations tested under in vitro conditions; however, this may not be true following the ingestion of herbal preparations when much higher plasma concentrations may be obtained. Effects will also vary with the tissue distribution of enzymes, and with the species used in testing since differences between species in enzyme activities also can be substantial. Additionally, in humans, marked interindividual variability in drug-metabolizing enzymes occurs as a result of genetic and environmental factors. This variability in xenobiotic metabolizing enzymes and the effect of flavonoid ingestion on enzyme expression and activity can contribute to the varying susceptibility different individuals have to diseases such as cancer. As well, flavonoids may also interact with chemotherapeutic drugs used in cancer treatment through the induction or inhibition of their metabolism.
Effects of flavonoids on gastrointestinal disorders
2001, Studies in Natural Products Chemistry
This chapter reviews the current literature about the effects of flavonoids on diseases of the gastrointestinal tract, namely gastric ulcer, diarrhoea, chronic inflammation and cancer. The activity-structure relationships and putative mechanisms of action are detailed whenever possible. Flavonoids exert a protective effect on gastric mucosa against experimental ulceration in which a number of mechanisms may participate, including blockade of acid secretion, a direct prostaglandin E₂-dependent cytoprotective effect, an antioxidative action and a bactericidal effect on Helycobacter pylori Flavonoids may ameliorate acute and chronic diarrhoea by inhibition of intestinal motility and secretion and may also be helpful in reducing chronic inflammatory injury in the gut by protecting it from oxidative stress and preserving mucosal function through an asyet unidentified mechamism. Despite initial reports on their carcinogenic potential, it appears that flavonoids behave predominantly as antimutagens/anticancerous agents. However, epidemiological demonstration of this effect in humans is not without controversy and further studies are much warranted. The mechanism of action is unclear but seemsto involve induction of apoptosis and specific antiproliferative activities rather than an unspecific toxic effect.

View all citing articles on Scopus

View full text

Comparison of the effects of feeding quercetin or flavone on hepatic and intestinal drug-metabolizing enzymes of the rat

Abstract

Biochim. biophys. Acta

J. biol. Chem.

Biochem. Pharmac.

Biochem. Pharmac.

J. biol. Chem.

J. biol. Chem.

Archs Biochem. Biophys.

J. biol. Chem.

Archs Biochem. Biophys.

Fd Chem. Toxic.

Activation and inhibition of benzo(a)pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids

Cancer Res.

Ethoxyresorufin: direct fluorimetric assay of a microsomal O-dealkylation which is preferentially inductible by 3-methylcholanthrene

Drug Metab. Dispos.

Pharmacological implications of microsomal enzyme induction

Pharmac. Rev., Lond.

Induction of benzypyrene hydroxylase by flavone and its derivatives in fetal rat liver explants

Biochem. Pharmac.

Activation and inhibition of benzo(a)pyrene and aflatoxin B₁ metabolism in human liver microsomes by naturally occurring flavonoids